Abbott discusses stent advancements

Abbott is committed to advancing treatment options and is pleased with the advancements of a new stent, it has asserted.

Senior vice-president of the company’s vascular division Robert Hance made this comment after it was announced the firm’s Xience Prime Everolimus Eluting Coronary Stent System had received the regulatory CE Mark.

The product, which is intended to treat coronary artery disease, should be launched in Europe in a broad size matrix with lengths of up to 38 mm during the third quarter of the year.

Mr Hance noted the Xience Prime builds on the clinical evidence from the Spirit group of clinical trials.

“The modified design features of the stent and delivery system are intended to make it easier for physicians to deliver the stent to the treatment area,” he said.

Abbott looks forward to making the innovative stent system available to physicians and patients alike across Europe in the coming months, Mr Hance concluded.

Earlier this month, the company initiated a clinical trial known as Spirit Prime to analyse the performance of the device.